Oncolytics Biotech Inc. ONCY
Oncolytics Biotech Inc. (Nasdaq: ONCY) is an oncology drug developer. Its lead program, Pelareorep, is in Phase 2 for Second-line RAS-mutated MSS metastatic colorectal cancer (randomized Phase 2 REO 033); also anal and pancreatic cancers.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Pelareorep + bevacizumab + FOLFIRI (REO 033) | Second-line RAS-mutated MSS mCRC (randomized Phase 2, site activation under way) | biologic-other | Phase 2 |
| Pelareorep + atezolizumab (GOBLET Cohort 4) | Relapsed unresectable squamous cell carcinoma of the anal canal (enrollment complete) | biologic-other | Phase 2 |
| Pelareorep + checkpoint inhibitor (planned pivotal) | Second-line or later SCAC (Fast Track July 2026; FDA aligned on pivotal design April 2026) | biologic-other | Phase 2 |
| Pelareorep | Metastatic pancreatic cancer (partnering sought) | biologic-other | Phase 2 |
| Pelareorep + RAS inhibitors | RAS-mutated solid tumors (preclinical) | biologic-other | Pre-clinical |
Recent results and decisions
- Oct 20, 2026started Oncolytics presents trial-in-progress abstract for REO 033 Phase 2 randomized study of pelareorep plus FOLFIRI/bevacizumab in second-line RAS-mutant MSS metastatic colorectal cancer.
The randomized, controlled, open-label study will evaluate patients with RAS-mutated, MSS mCRC who have progressed on first-line oxaliplatin-based therapy.
Filing - Jan 12, 2026positive Updated GOBLET Cohort 4 third-line anal cancer data: ORR about 29% (4 of 14 evaluable, 2 CR and 2 PR) with median DOR about 17 months, vs historical ORR of about 10% or less.
four of 14 evaluable third-line patients receiving pelareorep and atezolizumab achieved objective responses, resulting in an objective response rate (“ORR”) of approximately 29%.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.